Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Spiriva, Spiriva Respimat
Tiotropium is a long-acting, once-daily, inhaled anticholinergic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It belongs to a class of drugs known as muscarinic antagonists, specifically targeting the M3 muscarinic receptors in the lungs. By blocking these receptors, tiotropium relaxes the smooth muscles around the airways, allowing them to open up and improve airflow to the lungs.
For long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.
Outcome:
Increased anticholinergic side effects (dry mouth, constipation, blurred vision)
Mechanism:
Additive anticholinergic effects
Outcome:
Additive bronchodilatory effects (potential for adverse events)
Mechanism:
Synergistic effects on airway smooth muscle
Outcome:
Potential for altered drug metabolism
Mechanism:
Competition for metabolic enzymes
Most likely new formulation: Combination inhaler with a long-acting beta-agonist and a corticosteroid (2025, 70% confidence).
Based on consistent efficacy and safety data, tiotropium is expected to maintain its approved status for COPD treatment with a high likelihood (95%) of continued use in the next 5 years.
Anticholinergic, Bronchodilator
Quaternary Ammonium Compound